minocin mr 100mg modified release capsules
meda pharmaceuticals limited - minocycline hydrochloride - modified-release capsule - minocycline hydrochloride 100 mg - antibacterials for systemic use
tambocor 100mg tablets
meda pharmaceuticals limited - flecainide acetate 100 mg - tablet
leflunomide medac
medac gesellschaft für klinische spezialpräparate mbh - leflunomide - arthritis, rheumatoid - selective immunosuppressants - leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (dmard).recent or concurrent treatment with hepatotoxic or haematotoxic dmards (e.g. methotrexate) may result in an increased risk of serious adverse reactions, therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.moreover, switching from leflunomide to another dmard without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.
zoledronic acid medac
medac gesellschaft für klinische spezialpräparate mbh - zoledronic acid monohydrate - fractures, bone; cancer - drugs for treatment of bone diseases - prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.treatment of adult patients with tumour-induced hypercalcaemia (tih).
muse 125microgram urethral sticks
meda pharmaceuticals ltd - alprostadil - stick - 125microgram
breakyl 200microgram buccal films
meda pharmaceuticals ltd - fentanyl citrate - buccal film - 200microgram
breakyl 400microgram buccal films
meda pharmaceuticals ltd - fentanyl citrate - buccal film - 400microgram
breakyl 800microgram buccal films
meda pharmaceuticals ltd - fentanyl citrate - buccal film - 800microgram
carmustine medac (previously carmustine obvius)
medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastic agents - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).
bcg medac, powder and solvent for intravesical suspension
medac gesellschaft für klinische spezialpräparate mbh - bacillus calmette guérin (bcg) - powder and solvent for intravesical suspension - unknown - other immunostimulants; bcg vaccine